Keywords: Prana Biotech, Quintiles, Alzheimer's disease, Research funding, PBT2
Australia’s Prana gets funding for Ph II Alzheimer’s program via $2 million equity investment from Quintiles
Article | 30 June 2010
In a move that will help Australia’s Prana Biotechnology progress its planned Phase II clinical program in Alzheimer’s disease, the firm says that it had reached an agreement with leading clinical research provider Quintiles Transnational that will see the latter subscribe for up to $2 million in new Prana shares.
Q Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
